Elamipretide, a Mitochondrial-Targeted Drug, in the Treatment of Dry AMD
Time: 3:40 pm
day: Day One
- Elamipretide preclinical data showed reversal of AMD pathophysiology & improvement of vision
- A phase 1 open label safety study of elamipretide in patients with dry AMD showed improvements in multiple measures of vision
- A phase 2, randomized, double-masked, placebo-controlled clinical study of elamipreide in patients with dry AMD is on-going.